LNA043 clinical trials
Also written LNA043.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses LNA043 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LNA043
- 6
Studies by the year they started
6 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 2 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses LNA043 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.CompletedPhase 2Novartis PharmaceuticalsNCT03275064Written as LNA043
- Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee OsteoarthritisTerminatedPhase 2Novartis PharmaceuticalsNCT04864392Written as LNA043
- A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)TerminatedPhase 2Novartis PharmaceuticalsNCT04814368Written as LNA043
- Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis ParticipantsCompletedPhase 1Novartis PharmaceuticalsNCT04564053Written as LNA043
- Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte ImplantationTerminatedPhase 2Novartis PharmaceuticalsNCT03334812Written as LNA043
- First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee ReplacementCompletedPhase 1Novartis PharmaceuticalsNCT02491281Written as LNA043